AstraZeneca: one less indication in the US for Imfinzi
(CercleFinance.com) - AstraZeneca announced on Monday the withdrawal of its Imfinzi immunotherapy for the treatment of advanced bladder cancer in the US, a decision taken in agreement with the US FDA.
The biopharmaceutical group explains that the drug had been fast-tracked by the US health authority in 2017 due to encouraging clinical data from phase I/II trials.
The problem was that the phase III study did not reach its primary endpoint in 2020, a failure that has now led AstraZeneca to withdraw Imfinzi from the market for this indication, in accordance with the recommendations now established by the FDA.
The laboratory explains that Imfinzi remains approved in the US for the treatment of cancer, a speciality to which it now intends to devote all its attention.
The AstraZeneca share was down slightly (-0.3%) on Monday morning on the London Stock Exchange.
Copyright (c) 2021 CercleFinance.com. All rights reserved.